6-Chloro-5-methyl-1H-pyrazolo[3,4-b]pyrazine, 98%, 500mg

5-(Bromomethyl)-2-methylpyrimidin-4-amine hydrobromide, 95.0%, 1g

3-Amino-4-(1H-pyrazol-1-yl)benzoic acid, 95%, 100mg

Ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate, 95.0%, 5g

3-CHLORO-2-FLUOROBENZYL CHLORIDE, 95.0%, 1g

1,3-benzoxazol-2-yl 3-benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl sulfide, 98%, 100mg

(1R)-1-(2-Methylphenyl)propylamine hydrochloride, 95.0%, 250mg

5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dithione, 95%, 1g

3-Methoxy-4-methyl-benzoyl chloride, 95.0%, 1g

Triacetin>99.0%(GC)25g

(S)-1-tert-Butyl 2-ethyl 4-oxopiperidine-1,2-dicarboxylate, 95.0%, 5g

Microliter syringe GASTIGHT® series 1700 Point type 3, 250 µl, 1725 RNR, 1 piece

(E)-4-(2-(Hydroxyimino)acetamido)benzoic acid, 100mg